^
Association details:
| Biomarker: | KEAP1 mutation + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug Class: | Immunotherapy |
| Direction: | Resistant |
Evidence:
Source:
Title:
Clinical characteristics, co-mutations and outcomes of advanced non-small cell lung cancer (NSCLC) patients with KRAS mutations.
Published date:
05/19/2021
Excerpt:
Compared to KRAS+/KEAP1wt, KRAS+/ KEAP1+ pts had poor PFS (median 1.1 vs 7.5 m, p < 0.0001) and OS (1.1 vs. 27.8 m, p < 0.0001) measured from start of initial therapy....Our data shows that pts with KRAS co-mt with STK11/KEAP1 had worse PFS and OS with the addition of immunotherapy compared to chemotherapy alone
DOI:
10.1200/JCO.2021.39.15_suppl.e21174
